glp 1 receptor agonists beyond their pancreatic effects Glucagon-like peptide-1 in neoplastic diseases Overview of the proposed effects

How much IGF-1 Lr3 should be used

Age: Younger users (20s-30s) typically see faster results than older users (50s+), though older users often see more dramatic quality of life improvements

Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage

[1] This medication works by enhancing insulin secretion in response to meals, suppressing glucagon release, slowing gastric emptying, and reducing appetite

One of the ways CGA controls the abnormal microglia function may be by preventing activation of the NFB/P38 MAPK inflammatory axis and by suppressing the release of inflammatory proteins like TNF and IL1